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Abstract  
Introduction: Vaccination is the most important medical accomplishment; its 
effect on mortality reduction is unsurpassed by other medical achievements. Free 
circulation of people in the European Union (EU) and European Economic Area 
(EEA) has brought the need to analyze the different childhood immunization 
schedules among countries that form EU/EEA since; countries do not have a common 
immunization policy.  
Areas covered: The aim of this review is to analyze early childhood 
immunization programs across EU/EEA at the light of the existing evidence. The 
immunization programs were accessed throughout the European Centre for Disease 
Prevention and Control dataset.   
Expert commentary: The large variation observed, concerning both vaccines 
included and immunization schedules, between countries raises some questions and 
concern as; a child that moves from one country to another might easily miss a 
vaccine dose. Therefore, we present a recommendation, based on the available 
knowledge, for early childhood immunization schedule of the EU/EEA. To the best of 
our knowledge, this is the first review presenting a suggestion for early childhood 
immunization schedule in the EU/EEA. 
 	
Key	Words:		childhood, immunization, schedule, European Economic Area, vaccines. 	
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1. Introduction 
Vaccination is one of the most valuable medical accomplishments. Its effect on 
mortality reduction is unsurpassed by other medical achievements [1].  
Free circulation of people in the European Union (EU) and European Economic 
Area (EEA) has brought the need to analyse the different childhood immunisation 
schedules among the 28 countries that form the EU/EEA. Considerable variations 
were observed, concerning both vaccines included and immunisation schedules, 
among countries, which raise several questions and concerns. As an example, a child 
moving from one country to another can easily miss an administration and, thus, 
decrease immunisation compliance. Nevertheless, all schedules work and a child who 
is protected in accordance with a programme is well-protected.  
In this paper, we analyse the immunisation schedules of early childhood (until 
two years old), in 30 EU/EEA countries (28 EU countries plus Norway, Liechtenstein 
and Iceland) to highlight their similarities and differences considering the current 
evidence. Vaccination schedules of different countries were accessed through the 
European Centre for Disease Prevention and Control website (http://vaccine-
schedule.ecdc.europa.eu/Pages/Scheduler.aspx) between May 2016 and December 
2016.  
 
2. Vaccines included in childhood vaccination schedules across European 
Economic Area  
2.1. Tuberculosis vaccine 
The bacilli Calmette-Guérin (BCG) vaccines are the oldest of the vaccines 
currently used [2]. BCG vaccinations aim to provide protection against severe forms 
of childhood tuberculosis (TB), such as TB meningitis and miliary TB [3]. BCG 
vaccinations do not prevent infection by Mycobacterium tuberculosis (M. 
Tuberculosis) [4]. They also do not prevent reactivation of latent pulmonary 
infections [4], but rather help the host to delay the growth of organisms in the lungs 
and lymph nodes, as this prevents their dissemination [2]. However, this is a very 
controversial vaccine, since its effects in randomised controlled trials and case studies 
have been inconsistent; some have demonstrated a great degree of protection, and 
others have not displayed any benefits [2,5].  
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This is a live attenuated vaccine that is dispensed using an intradermal route of 
administration with a syringe and needle, as the dosage can be measured precisely and 
the administration can be controlled; the deltoid is the most common site for 
administration [2]. As a live attenuated vaccine, it is expected to induce a T-
dependent response; BCG-induced T-cells contribute to macrophage activation, and 
antibody production is inefficient [2]. 
The recommended dosage depends on the vaccine strain and the age of the 
receiver [2]. Some BCG strains are considered strong and others weak. Strong strains 
are more immunogenic, and provide better protection than weaker strains [2]. 
However, there is no agreement about which strain of BCG is optimal for universal 
use [2,5].  
Nowadays, in the EU/EEA, only 10 countries (Figure 1) utilise BCG vaccines in 
their childhood immunisation schedules. All of them administer these vaccines once, 
from birth until the seventh day of life. However, the literature is not consensual 
concerning the age of administration. A clinical trial has demonstrated that delaying 
BCG vaccinations from birth to 10 weeks of age results in an enhanced memory T-
cell response [6]. Furthermore, delaying the vaccinations until nine months of age was 
demonstrated to result in higher rates of immunogenic sensitivity in children [2]. 
Conversely, another clinical trial demonstrated that delaying BCG vaccinations from 
birth until 18 weeks of age lead to a decrease in Th1 responses [7]. However, delaying 
tuberculosis vaccinations would mean that the child would be unprotected for several 
months.   
Studies have indicated that BCG might reduce childhood mortality from other 
causes, presumably because BCG promotes a T-helper-1 immune response [3]. 
Newborns vaccinated with BCG in the first days of life seem to develop a Th1 
response, while non-vaccinated infants develop a Th2 response [8]. Therefore, BCG 
vaccines might stimulate the immune system and prevent anergy. Furthermore, 
children vaccinated after the first month of life were less anergic than children 
vaccinated during the first month [8]. BCG may have a more general effect on the 
immune system beyond protection against severe forms of childhood tuberculosis [8]. 
Authors have reported that BCG vaccines might be associated with a lower 
prevalence of anergy and might impact cellular immunity to other antigens, apart 
from tuberculin [8]. Furthermore, it seems that BCG vaccines induce nonspecific 
protection against distinct pathogens via epigenetic reprogramming of monocyes [9]. 
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Kleinnijenhuis et al. [10] have documented that BCG vaccines can induce two distinct 
types of immune responses: a specific immune response involving antigen-specific T 
cells and memory conducting to protection against TB, and the induction of adaptive-
trained immunity based on functional reprogramming of mononuclear phagocytes that 
leads to protective effects not only against TB, but also against other infections. 
Moreover, a recent study conducted in Spain indicated that BCG vaccinations might 
have additional protective effects against moderate to severe forms of respiratory 
infections sepsis requiring hospitalisation [11]. Therefore, studies have indicated that 
BCG vaccines might have nonspecific benefits [9,12]. However, it is difficult to 
conclude that BCG vaccines might have nonspecific benefits, since several 
confounding factors exist.  
The World Health Organisation (WHO) recommends vaccination as soon as 
possible after birth in high-burden countries [4]. Countries with a low burden may 
choose to limit BCG vaccinations to neonates and infants of recognised high-risk 
groups [4]. 
 
Figure 1: BCG primary immunisation schedules across European Union/European Economic Area. 
 
  
BCG 
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2.2. Rotavirus vaccines 
Rotavirus infection is the main cause of severe dehydrating diarrhoea disease in 
infants and toddlers worldwide [13]. Rotavirus is mainly transmitted by faecal-oral 
route [13], and between ages two and three, virtually all children are infected [2].   
Even though WHO recommends that rotavirus vaccines should be included in all 
national immunisation programmes and considered a priority [14], only nine EU/EEA 
countries presently include it in their immunisation plans (Figure 2). Each country has 
its own immunisation schedule: seven countries administer the first dose at age two 
months, while two countries administer it at age six weeks; four countries dispense 
two doses, while five countries dispense two or more, depending on the chosen brand.  
There are two available oral vaccines in the European market: Rotateq®, a 
pentavalent vaccine (RV5); and Rotarix®, a monovalent vaccine (RV1). The two 
vaccines differ in strain composition and administration schedules. Given the huge 
diversity and capability of the human rotavirus to change, vaccines need to efficiently 
protect against major circulation strains [13]. Rotarix® is an oral, live-attenuated 
human rotavirus of entirely human origin, vaccine-derived from the most common 
circulating wild-type strain G1P [13]. Its vaccination course consists of two doses, 
and the first dose may be administered at age six weeks. There should be an interval 
of at least four weeks between doses [15]. The vaccination course should preferably 
be administered before 16 weeks of age and should be completed by age 24 weeks. 
Rotateq® is an oral, live, human-bovine, reassortant, multivalent, rotavirus vaccine. It 
contains five live, human-bovine, reassortant rotavirus strains: VP7 (G) types, 
including G1, G2, G3, and G4, and VP4 (P) type [13]. Its vaccination course requires 
three doses [16]. According to the manufacturer, the first dose may be administered 
from the age of six weeks and no later than 12 weeks. There should be at least a 4-
week interval between doses. The vaccination course should be completed by age 20 
to 22 weeks. If necessary, the last dose may be given up to the age of 32 weeks. Both 
vaccines can diminish the number of rotavirus gastroenteritis cases [13]. 
Rotavirus vaccines have been associated with a short-term risk of intussusception, 
especially after the first dose and between one to seven days after vaccination [17]. A 
recent study has indicated that there is an increased risk for intussusception one to 
seven days after the first dose, for both vaccines, when the infant is three to five 
months of age [18].  
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Figure 2: Rotavirus primary immunisation schedules across European Union/European Economic 
Area.  
 
 
 
 
2.3. Diphtheria 
Diphtheria is an acute communicable respiratory disease [2] that occurs mainly in 
tropical countries and is rare in industrialised countries [19]. Diphtheria was a major 
cause of childhood mortality before the implementation of specific immunisations [2].  
The bacterial exotoxin and its cell-wall components, as O- and K- antigens, are   
important in the disease pathogenesis [20]. However, the most important virulence 
factor of C.dipheteriae is the exotoxin, which can cause local and systemic 
destruction [20].  Diphtheria vaccine is a toxoid and is adsorbed onto an adjuvant [2]. 
Presently, it is almost exclusively administered in combination with tetanus toxoid or 
with tetanus and pertussis vaccines in order to reduce the number of injections [20]. It 
can also be combined with hepatitis B and Haemophilus Influenza type b. Intriguingly, 
no controlled clinical trial of the efficacy of the toxoid in preventing diphtheria has 
been conducted [2]. Solid evidence supporting the effectiveness of the vaccine has 
arisen from observational studies [2].   
Rotavirus vaccine 
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Severe forms of local and systemic disease demand an immune response that is 
dependent on the antitoxin antibodies of IgG type, while type-specific protection 
against carriage and mild forms of local disease is induced by antibodies to the 
variable K-antigens of the bacterial cell wall [20]. However, cell-mediated immunity 
might also play a role [20]. Antibody levels of 1.0 IU/mL are associated with long-
term protective immunity, whereas circulating anti-toxin levels below 0.01 IU/mL do 
not provide protection against the disease [20].. Therefore, suffering from the 
infection might not confer protective immunity [20]. 
In the EU/EEA, diphtheria is included in all vaccination schedules [21]. However 
the vaccination schedule varies considerably among countries. Presently, the first 
dose is given at age two months in 22 countries, and at age three months in eight 
countries (Figure 3). Certain countries, such as Austria, Denmark, Iceland, Norway, 
Sweden and Finland, use identical schedules at three, five, and 12 months. Others, 
such as Portugal, Spain, and Lithuania, use two, four, six, and 18 months. The United 
Kingdom uses two, three, and four months. (Figure 3) Throughout the EU/EEA, 
variability is observed not only concerning primary series, but also regarding the age 
for boosters (Table 1). For example, in Germany, the primary series is two, three, and 
four months, and the first booster is between age 11 and 14 months; in Belgium, 
Bulgaria, the Czech Republic, Hungary, Luxembourg, Malta, and the Netherlands, the 
primary series is two, three, and four months for all countries, but the first booster is 
administered at the age of 15, 16, 10, 18, 13, 18, and 11 months, respectively.  
WHO recommends that the first dose should be administered as early as six 
weeks of age, followed by second dose in the 10th week and the third in the 14th 
week of life [20]. Maternal antitoxin levels affect the immune response of infants, 
even though high maternal antibody titres suppress, but do not prevent, adequate 
responses of infants to two doses of vaccines; after the third dose, the suppressive 
effect is gone [2]. Therefore, some interfering is likely between maternal antibodies 
and the diphtheria vaccine [22]. However, after three doses, practically all infants 
develop levels of antibodies greater than 0.01 IU/mL [2]. 		
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2.4. Tetanus  
The pathogen responsible for tetanus, an acute fatal disease that leads to 
generalised rigidity and convulsive spasms of skeletal muscles, is found in the 
environment [2,19]. Many animals can harbour and excrete the organism and its 
spores [2,19].  
Tetanus vaccine is a toxoid and is acquired through a C. tetani strain [2]. The 
protection is achieved through an antibody-dependent path and depends upon the 
ability of antitoxins to neutralise tetanospasmim, the most important toxin of C. tetani 
that blocks inhibitory neurotransmitters in the central nervous system and causes 
muscular stiffness and spasms [23]. However, the primary immunisation with tetanus 
toxoid also induces cellular immune responses in a high percentage of subjects [2]. 
Moreover, protection to tetanus can be only achieved by active and passive 
immunisation, recovering from the disease does not result in protection against it [23]. 
This vaccine, as other inactivated and toxoid vaccines, requires more than one dose to 
confer protection [2]. Normally, protective concentrations of antitoxins are achieved 
with two doses, and the third allows immunity in 100% of immunised subjects [23].   
Studies have indicated that maternal-transmitted antibodies for tetanus toxoid do 
not interfere with neonatal responses when the vaccine is given soon after birth [22]. 
For the tetanus vaccine, the age at first dose does not seem critical, owing to its great 
immunogenicity [22]. Therefore, no matter what age the first dose is provided, an 
equally beneficial immune response will be achieved [22]. Consequently, protective 
levels can be obtained with schedules starting in the newborn period [2]. WHO 
suggests that the primary series of three doses should be administered before the age 
of one year [23]. Additionally, an interval of at least four weeks between doses is 
recommended [23]. WHO recommends that the first dose, since it is dispensed in 
combination with diphtheria and pertussis, should be administered as early as six 
weeks of age, since pertussis is of particular risk for young infants [23]. However, the 
vaccination schedule among EU/EEA countries is heterogeneous, and no country 
administers the vaccine at age six weeks; the first dose is given at age two months in 
22 countries, and at age three months in eight countries (Figure 3). Some countries, 
such as Austria, France, Denmark, Iceland, Norway, Sweden, and Finland, use 
identical schedules at three, five, and 12 months; others, such as Portugal, Spain, and 
Lithuania, use two, four, six, and 18 months; the United Kingdom uses two, three, and 
four months (Figure 3).  
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2.5. Pertussis   
Pertussis, or whooping cough, is an acute respiratory infection that results in a 
protracted intense cough that last for weeks, and is more severe in children [2,19]. 
This infection was one of the most common childhood diseases in the United States of 
America during the 20th century [19]. Despite the efficiency of the pertussis vaccine 
in preventing the disease, it has little impact on the circulation of B. Pertussis, even in 
countries with elevated vaccination coverage [24]. This makes unvaccinated children 
and susceptible individuals (adolescents, adults, and older subjects) reservoirs that are 
able to transmit it, allowing the occurrence of pertussis outbreaks [24]. It is during the 
first three months of life that hospitalisation and mortality rates are higher for 
pertussis [25]. It seems that pertussis is far from being controlled in the EU/EEA, and 
is still a pertinent public health concern [26,27]. Therefore, pertussis is the least 
controlled of the vaccine-preventable diseases in the EU/EEA [28]. In 2014, 40,727 
cases were reported from EU/EEA countries, a higher number than in 2013 [28]. The 
highest rates were in children below one year of age (51.6 cases per 100,000 
population), and 83% of these cases were under six months of age [28]. Since 2013, 
significant increases in the notification rate were observed in the Netherlands, the 
Czech Republic, Slovenia, Denmark, Belgium, Sweden, and Lithuania [28].  
The objective of the pertussis vaccination is to reduce the incidence and the 
likelihood of severe pertussis in childhood [24]. Two vaccines are available: the 
whole-cell vaccine, and the acellular pertussis vaccine [2]. Whole-cell vaccines are 
suspensions of inactivated  B. Pertussis,, while acellular pertussis vaccines are subunit 
vaccines that contain purified inactivated components of B. Pertussis [2,19]. The 
acelullar pertussis vaccine was formulated due to the common occurrence of minor, 
but undesirable, adverse local reactions; and some, less frequent, systemic reactions 
that have been associated with whole-cell vaccine administration, raising concerns 
about its safety [2]. Furthermore, adverse reactions of the whole-cell pertussis vaccine 
tend to increase with age and number of doses; thus, it is not recommended for 
immunisation of adolescents and adults [24]. The acellular vaccine is less reactogenic, 
and adverse reactions are minor and less frequent [2]. Acellular vaccines and whole-
cell vaccines have similar efficacy rates, more than 85% [24]. However, it seems that 
the duration of protection is shorter with the acellular vaccine [29]. Pertussis 
incidence is also increasing in countries where the whole-cell vaccine is in use [29].. 
Therefore, the fading immunity induced by the acellular vaccine is not the main 
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reason for the resurgence of pertussis [29]. One possible explanation for pertussis 
resurgence is that the acellular vaccine does not prevent transmission of B. pertussis, 
although it protects against the disease, and none of the vaccines prevent disease from 
virulent B. pertussis [29].  
The majority of EU/EEA countries now utilise the acellular vaccine in their 
immunisation schedules [22]. Various acellular pertussis vaccines are available for 
specific age groups, and they are different in terms of component concentrations [19]. 
Acellular vaccines elicit the production of antibodies as well as T-cell specific 
responses to vaccine antigens, and Th1 cells seem to be involved in the immune 
responses [2]. Maternal antibodies do not seem to affect responses to vaccination 
[22].  . Thus, it seems improbable that transplacentally-acquired antibodies restrain 
vaccine-induced immune responses [22].   
WHO recommends that the first dose of the pertussis vaccine should be 
administered as early as six weeks of age, since pertussis is of particular risk for 
young infants, followed by a second dose at 10 weeks and a third at week 14 of life 
[24].  In addition, according to clinical trials, it seems that whole-cell and acellular 
vaccines that are given in combination with diphtheria and tetanus can be safely 
administered very early in life [24]. However, evidence is still not sufficient to 
support the implementation of pertussis vaccines in newborns [24]. Nevertheless, 
vaccination schedules among EU/EEA countries are heterogeneous, and no country 
administers the vaccine at age six weeks, as recommended by WHO. The first dose is 
given at age two months in 22 countries, and at age three months in eight countries 
(Figure 3). Countries such as Austria, France, Denmark, Iceland, Norway, Sweden, 
and Finland use identical schedules at three, five, and 12 months; others, such as 
Portugal, Spain, and Lithuania, use two, four, six, and 18 months; the United 
Kingdom uses two, three, and four months (Figure 3). Therefore, the primary 
schedules in EU countries can be grouped as follows: three doses at two, three, and 
four months; three doses at two, four, and six months; and two doses at three and five 
months. The observed discrepancies between countries for the primary schedule of 
the pertussis vaccine is an issue, since an early protection for pertussis is an important 
goal to achieve [30].  The schedule of two, three, and four months results in an early 
protection [22]. And, it is not known, due to lack of studies, if the schedule of two, 
four, and six months already induces immunological memory with the first two doses 
[22]. Aditionally, in the schedule of two, three, and four months, protection is 
		
	 11	
achieved one month earlier than with the schedule of three and five months, but it 
requires an additional dose [22]. All the existing schedules induce priming with 
success; the benefits of an early protection favour early implementation schedules. A 
possible and apparently effective strategy to ensure early protection is maternal 
immunisation between 28 and 38 weeks of gestation [29]. Another future strategy 
may consist of a new vaccine that in currently under clinical development [29].   
 
Figure 3: Diphtheria, tetanus and pertussis primary immunisation schedules across European 
Union/European Economic Area. 
 
 
 
2.6. Poliomyelitis 
Poliomyelitis is an acute communicable disease and can be caused by any of three 
serotypes of poliovirus: type 1, type 2, and type 3 [31]. In 2012, polio eradication was 
considered by the World Health Assembly a global public health emergency, 
consequently the Polio Eradication and Endgame Strategic Plan 2013-2018 was 
developed [31].   
2,3,4 months 
3,5 months 
2,4,6 months 
3,4-5,6 months 
2,4 months 
2,3-4,5-6 months 
2-3,4-5 months 
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With the widespread of poliovirus vaccination, type 2 poliovirus has not been 
detected since 1999 [32]. And, type 3 has not been detected since November 2013 
[32].  However, type 1 remains in circulation [32]. Poliovirus was, in the pre-
vaccination period, the primary cause of permanent disability in children [2]. The 
viruses are spread by faecal-to-oral and oral-to-oral transmissions [31]. The poliovirus 
initially replicates in the gastrointestinal tract, but it can affect the central nervous 
system, leading to flaccid paralysis of the muscles [2]. 
There are two types of poliovirus vaccines: the inactivated poliovirus vaccine 
(IPV), and the live oral poliovirus vaccine (OPV). IPV is the vaccine of choice in 
areas free of poliovirus or with very low levels. Therefore, it is the vaccine used in the 
EU/EEA schedules with the exception of Poland, which uses a booster of OPV at the 
age of six years.  
IPV contains all three serotypes of poliovirus, and is an inactive antigen vaccine 
[2]. This vaccine development is based on the inactivation of cell-culture-derived 
polioviruses using formaldehyde [31]. It is available as a stand-alone vaccine or in 
combination with DTP, hepatitis B, and haemophilus influenza type B infection 
vaccines [31]. It is considered a very safe vaccine with no major side effects [31]. 
IPV immunogenicity depends of a number of factors, such as number of doses, 
interval between doses, level of maternally-acquired poliovirus antibodies present at 
the time of vaccination that can suppress the immune response, and IPV type [2]. In 
the EU/EEA, primary vaccine schedules vary considerably among countries. Some 
countries have a two-dose schedule at three and five months, such as Austria, 
Denmark, Finland, and Iceland; others have a three-dose schedule that can either be 
administered at two, three, and four months, as in Belgium and the Czech Republic, 
or at two, four, and six months, as in Portugal, Ireland, and Spain. The first booster 
after the primary schedule also varies considerably. For example, in Austria, 
Denmark, Finland, Iceland, it is administered at age 12 months, Belgium provides it at 
age 15 months, the Czech Republic dispenses it at age 10 months, and Portugal 
administers it at age 18 months. Concerning primary immunisations, studies have 
indicated that seroprotection rates are clearly superior when three doses are 
administered, particularly when the schedule of two, four, and six months is utilised 
[2]. Schedules of three, four, and five months, and two, three, and four months also 
provide good protection rates; however, they are not as effective as the schedule of 
two, four, and six months [2]. WHO recommends a primary series of three doses of 
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IPV, beginning at the age of two months [31]. If an early schedule as, for example, 
six, 10 and 14 weeks of age is adopted, a booster should be dispensed after an interval 
of at least six months [31]. In the EU/EEA, the poliovirus vaccine is provided in 
combination with diphtheria, tetanus, and pertussis; thus, the primary schedule is 
coincidental (Figure 3).  
 
2.7. Haemophilus Influenza Type B Infection  
Haemophilus influenzae, a pathogen that spreads from person to person via 
respiratory droplets, is responsible for considerable morbidity and mortality in 
children under the age of five years [2]. Prior to the pre-vaccine era, H. influenzae 
serotype b (Hib) was responsible for 95% of invasive diseases [2]. The occurrence of 
this disease is relatively infrequent in the first two months of age, probably due to 
protection from maternal antibodies acquired thought the placenta [33]. The greatest 
disease burden is observed between four and 18 months of age [33]. The widespread 
of the H. influenzae b vaccine led to large reductions in the incidence of invasive Hib 
diseases (decrease of 90%) [33]. Invasive diseases include meningitis, pneumonia, 
septic arthritis, osteomyelitis, pericarditis, cellulitis, and epiglottitis [33]. Even with 
adequate medical treatment, 5% of children with H. influenzae b meningitis die, and 
20 to 40% of survivors suffer from severe sequela [33]. 
Haemophilus influenzae is a gram-negative coccobacillus, and its polysaccharide 
capsule is the major virulence factor for severe disease [2]. The serotype b capsule as 
well as other aspects makes it particularly virulent [2]. Since the pure polysaccharide 
vaccine was not effective in children under 18 months of age, and the greatest disease 
burden is observed in children younger than two years of age, a conjugated vaccine 
(bound of the polysaccharide with a carrier protein, i.e. diphtheria protein, tetanus 
toxoid, or meningococcal membrane protein) was created in order to improve its 
immunogenicity in young children [2,19]. If the immune response for the first vaccine 
was a typical, T-independent antigen response, which is age-dependent, so it fail to 
induce immunological memory in the youngest children. [2,19,33]. The conjugated 
vaccine turns the immune response into a T-dependent B-cell immune response that 
produces longer immunity, and immunological memory is induced [2,19,33].  
In the EU/EEA, primary vaccine schedules vary considerably. Some countries 
have a two-dose primary schedule at three and five months, as in Austria, Denmark, 
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Finland, and Iceland. Others have a three-dose schedule that can either be 
administered at two, three, and four months, as in Belgium, the United Kingdom, and 
the Czech Republic, or two, four, and six months, as in Portugal and Spain. The first 
booster after the primary schedule exists in all schedules, but it also varies 
considerably: in Austria, Denmark, Finland, and Iceland, it is administered at age 12 
months, the United Kingdom dispenses it between age 12 to 13 months, Belgium 
provides it at age 15 months, Netherlands dispenses it at 11 months of age, the Czech 
Republic administers it until age 18 months, and Portugal, Hungary, Spain, and Malta 
provide it at age 18 months. In the EU/EEA, the Hib primary vaccination is 
administered in combination with diphtheria, tetanus, pertussis; thus, the primary 
schedule is coincidental (Figure 3). Evidence has indicated that at least three doses are 
needed to achieve vaccine efficacy and effectiveness [33]. These can be achieved with 
three primary doses with or without a booster (3p+0 or 3p), or with two primary doses 
and a booster (2p+1) [33]. However, all countries of the EU/EEA provide a booster 
dose around the second year of life, as the vaccine-induced antibody wanes over time, 
leading to an increase susceptibility to disease [34]. A recent systematic review 
indicated that 3p+1 and 2p+1 schedules achieve similar immunological responses 
[35].Therefore, it seems that the primary schedule of two or three doses confer 
identical short-term levels of protection [33]. Since serious Hib disease occurs most 
frequently in children aged between four and 18 months, WHO recommends that 
immunisation should start from six weeks of age, or as early as possible thereafter 
[33].  
 
2.8. Hepatitis B 
Hepatitis B virus (HBV) infection is a highly prevalent infection around the globe, 
and approximately 30% of the world’s population has serologic evidence of HBV 
infection [2]. HBV is a leading cause of chronic hepatitis and cirrhosis, causing 
significant morbidity and mortality worldwide [2]. It is also the leading cause of 
hepatocellular carcinoma [2]. Transmission is believed to be through percutaneous or 
mucosal exposure with body fluids from persons who have acute or chronic disease 
[19]. The disease outcome is age-dependent [36]. For infants that acquire the disease 
from their mother or in infancy, the odds of being chronically infected are 90% [19]. 
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Children that become infected between age one year and five years of age have a 30% 
to 50% chance of chronic infection [19].  
Hepatitis B vaccine is available as a monovalente formulation or in combination 
with diphtheria-tetanus-pertussis, Hib, hepatitis A, and inactivated polio [36]. 
Nowadays, hepatitis B vaccine is a recombinant vaccine [2]. The active substance in 
recombinant hepatitis B vaccine is a hepatitis B surface antigen that is produced in 
yeast or mammalian cells [36]. 
WHO considers that perinatal and early postnatal transmission is a significant 
cause of chronic infections worldwide [36]. Thus, WHO recommends the 
administration of hepatitis B vaccine as soon as possible after birth, preferably in the 
first 24 hours, even in low-endemicity countries [36]. This dose should be followed 
by two or three doses with a minimum interval of four weeks to complete the primary 
series [36]. According to WHO the following two schemes to complete the primary 
series are appropriate: a three-dose schedule where the first dose (monovalent) is 
administered at birth, and the second and third dispensed simultaneously as the first 
and third doses of the DTP vaccine; or a four-dose schedule, in which a monovalent 
birth dose is followed by three monovalent or combined vaccine doses [36]. Previous 
evidence does not support the need of a booster [36]. 
Twenty-three member states of the EU/EEA included hepatitis B in their 
immunisation schedules: eight targeted newborn babies, 12 targeted infants with two 
months of age, two targeted children with three months of age, and one targeted 
children with 12 months of age. Eight countries (Denmark, Finland, Hungary, Iceland, 
Liechtenstein, Norway, Slovenia, Sweden, and the United Kingdom) do not have 
hepatitis B vaccine in their routine childhood immunisation programme (Figure 4); it 
is only provided to certain well-defined risk groups. In the rest of the countries, the 
primary schedules vary significantly. For example, in Bulgaria, Estonia, and 
Lithuania, it is administered at birth, one month of age, and six months of age; in 
Portugal and Spain, it is administered at birth, two months, and six months of age; and 
in Croatia and Ireland, it is dispensed at age two, four, and six months (Figure 4).  
According to WHO, the timely delivery of a birth dose of hepatitis B vaccine 
should be a performance measure for all immunisation programmes [36]. In addition, 
WHO recommends that all infants should receive the first dose as soon as possible 
after birth, that is, within 24 hours of birth, even in countries with low and 
intermediate endemicity [36]. 
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Figure 4: Hepatitis B primary immunisation schedules across European Union/European 
Economic Area. 
 
2.9. Pneumococcal Disease  
Streptococcus pneumoniae is an asymptomatic coloniser of the nasopharynx, and 
can cause serious diseases as pneumonia, meningitis, bacteraemia, as well as milder 
and more common illnesses, such as sinusitis and otitis media [2,37]. This agent is 
mostly transmitted through respiratory droplets, and the main reservoir is believed to 
be infants and young children [37]. More than 90 pneumococcal serotypes have been 
identified [2], and the distribution of serotypes that cause disease varies by age, 
disease syndrome, disease severity, geographic region, and over time [37]. In the 
EU/EEA, the highest levels of infection, before the introduction of a vaccine, were in 
children with two years of age or younger [2]. Streptococcus pneumoniae 
antimicrobial resistance is a matter of major concern, and as pneumococcal infections 
become increasingly more difficult to treat, the focus should be placed on preventing 
the disease through vaccination [38]. 
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Streptococcus pneumoniae is a gram-positive, encapsulated diplococcus, and its 
polysaccharide capsule is one of the primary factors responsible for the virulence of 
this bacterium [2,37]. Two types of vaccines are available: the pneumococcal 
polysaccharide vaccine (PPV23), and the pneumococcal conjugate vaccines (PCV7, 
PCV10 and PCV13) [39] 
Pneumococcal polysaccharide vaccine is associated with poor or absent 
immunogenicity in children below two years of age [37].  These vaccines fail to elicit 
a protective immune system response among infants and very young children since 
children respond poorly to T-independent antigens [40]. Conversely, the 
pneumococcal conjugate vaccine enhances the antibody response and induces 
effective immune memory in children below two years of age, by changing the nature 
of the antipolysaccharide response from T-independent to T-dependent. 
 [37]. Additionally, conjugate vaccines can reduce nasopharyngeal carriage of 
vaccine type pneumococci, and has effectiveness against serotypes currently causing 
most invasive diseases, and evidence for effectiveness against non-invasive 
syndromes, including non-bacteraemic pneumonia and otitis media [40,41].  
Pneumococcal immunisation schedules across the EU/EEA vary greatly among 
countries in terms of age groups and vaccines administered [39]. Currently, the 
pneumococcal vaccine is dispensed in routine immunisation programmes either in a 
2p +1 or 3p+1 schedule (Figure 5). For example, in Belgium, Hungary, Luxembourg, 
Portugal, Spain, and the United Kingdom, primary immunisation is at two and four 
months, and a booster is given at age 12 months; in Denmark, Finland, Iceland, and 
Sweden, the primary immunisation is administered at three and five months of age, 
and a booster is given at age 12 months; in Bulgaria, the Czech Republic, Greece, 
Italy, and Slovenia, the primary immunisation schedule is at age two, three, and four 
months, and a booster is given around age 11 months. WHO recommends three 
primary doses, or as an alternative, two primary doses plus a booster [37]. According 
to WHO, when choosing between a 3p or a 2p+1 schedule, countries should consider 
particularities such as epidemiology of the disease, local factors, and timeless of doses 
[37]. For example, if the peak of the disease is observed in young infants with less 
than 32 weeks of age, a 2p+1 schedule might not offer the optimal protection for 
certain serotypes compared to the 3p+0 schedule [37], thus, the second scheme should 
be favoured. However, the third dose, in the 2p + 1 scheme, induces higher antibody 
levels compared to the 3p+0 schedule, and this may be important for the duration of 
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protection or effectiveness against some serotypes [37]. According to WHO, if a 3p+0 
schedule is the option, vaccination can be initiated as early as six weeks of age with 
doses given at six, 10 and 14 weeks, or at two, four, and six months, depending on 
convenience [37]. However, if a 2p+1 schedule is the choice, WHO recommends that 
the first dose be administered as early as six weeks of age, with the second at an 
interval of 8 weeks or more, and the booster should be dispensed between nine to 15 
months of age [37].  
 
Figure 5: Penumococcal primary immunisation schedules across European Union/European 
Economic Area. 
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 Table 1. Primary immunisation and first booster doses across European Union/European Economic Area.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B= Birth; Ba=1-5 days after birth; Bb= 2-7 days after birth; Hib= Haemophilus influenzae type B. 
 Tuberculosis Rotavirus  Diphtheria Tetanus Pertussis Poliomyelitis Hib Hepatitis B Pneumococcal  
Austria  3 2p+1 2p+1 2p+1 2p+1 2p+1 
Belgium  3 3p+1 3p+1 3p+1 3p+1 2p+1 
Bulgaria B  3p+1 3p+1 3p+1 3p+0 3p+1 
Croatia B  3p+1 3p+1 3p+1 3p+0  
Cyprus   3p+1 3p+1 3p+1 3p+1 2p+1 
Czech Republic   3p+1 3p+1 3p+1 3p+1 3p+1 
Denmark   2p+1 2p+1 2p+1  2p+1 
Estonia Ba 2 4p+1 3p+1 3p+1 3p+0  
Finland  3 2p+1 2p+1 2p+1  2p+1 
France   2p+1 2p+1 2p+1 2p+1 2p+1 
Germany  2 3p+1 3p+1 3p+1 2p+1  2p+1 
Greece   3p+1 3p+1 3p+1 2p+1 3p+1 
Hungary B  3p+1 3p+1 3p+1  2p+1 
Iceland   2p+1 2p+1 2p+1 B 2p+1 
Ireland B  3p+0 3p+0 3p+1 3p+0 2p+1 
Italy   3p+1 3p+1 3p+1 3p+1 3p+1 
Latvia B 3 3p+1 3p+1 3p+1 3p+1 2p+1 
Liechtenstein   3p+1 3p+1 3p+1   
Lithuania B  3p+1 3p+1 3p+1 3p+0 2p+1 
Luxembourg  2 3p+1 3p+1 3p+1 2p+0 2p+1 
Malta   3p+1 3p+1 3p+1 2p+1   
Netherlands   3p+1 3p+1 3p+1 3p+1 2p+1 
Norway  2 2p+1 2p+1 2p+1  2p+1 
Poland B  5p+1 2p+1 2p+1 3p+0  
Portugal B  3p+1 3p+1 3p+1 3p+0 2p+1 
Romania Bb  2p+1 2p+1 2p+1 3p+1  
Slovakia   4p+1 2p+1 2p+1 4p+1 4p+1 
Slovenia   4p+1 3p+1 3p+1  3p+1 
Spain   3p+1 3p+1 3p+1 3p+0 2p+1 
Sweden   2p+1 2p+1 2p+1  2p+1 
United Kingdom  2 3p+0 3p+0 3p+1  2p+1 
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2.10. Meningococcal Disease  
Neisseria meningitides is recognised as a leading cause of meningitis and 
fulminant septicaemia in several countries, posing a significant public health problem 
[42]. N. meningitides is a fastidious, gram-negative, endotoxin-producing organism 
that usually resides asymptomatically in the human nasopharynx and is easily 
transmitted by respiratory droplets [2,42]. The serogroups A, B, C, X, W-135, and Y 
are medically significant, and the main cause for invasive meningococcal infections 
[42,43]. These serogroups vary considerable in time and with geographic location 
[42]. In Europe, the majority of cases are caused by serogroup B, particularly in 
countries that have introduced serogroup C meningococcal conjugate vaccines [42]. 
However, in England and Wales, an increase in meningococcal group W has been 
observed [44]. In addition, in some EU/EEA countries, particularly Scandinavian 
countries, an increase of meningococcal Y has been reported [43]. The disease mainly 
affects children and adolescents, as the highest rates occur in infants aged three to 12 
months [42]. Invasive diseases can cause, aside from meningitis and septicaemia, 
arthritis, myocarditis, pericarditis, and endophtalmitis [42]. Meningococcal disease 
can advance rapidly and death can occur, even with medical attention [2]. Devastating 
long-term sequelae may lead to permanent disability [45].  
Presently, polysaccharide and conjugated polysaccharide meningococcal vaccines 
are accessible [46]. Conjugate vaccines reduce nasopharyngeal carriage and, hence, 
interruption of transmission and establishment of population protection; and are 
effective in protecting young children (<24 months) who may respond poorly to 
conventional polysaccharide vaccines [46]. Meningococcal conjugate vaccines are 
available as monovalent (A or C), quadrivalent (A, C, Y and W), and combined 
(serogroup C or C and Y, along with Haemophilus influenzae b) vaccines [46]. The 
development of a successful vaccine against serogroup B was challenging due to 
several factors so, the existent vaccine is based on conserved proteins, using “reverse 
vaccinology” [46]. 
According to WHO countries with high (>10 cases/100,000 population/year) or 
intermediate (2-10 cases/100,000 population/year) endemic rates of invasive 
meningococcal disease as well as, countries with frequent epidemics should include 
meningococcal vaccine in their immunisation plan [42]. In the EU/EEA, only 13 
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countries have the vaccine for meningococcal C in their routine immunisation 
programmes, and even fewer have meningococcal B vaccine in their routine 
immunisation plans (Figure 6). WHO recommends that monovalent meningococcal C 
vaccine is to be administered only once in children aged more than 12 months, and in 
children between two to 11 months two doses plus a booster should be provided [42]. 
However, it is not known, for sure, if boosters are needed after primary vaccination at 
12 or more months of age [42].Therefore, Belgium administers it at age 15 months; 
Cyprus between 12 to 13 months of age; France and Portugal at 12 months of age; 
Germany between age 12 to 23 months of age; Greece at age two, four, six, and 23 
months; Iceland between age six to eight months of age; Ireland at age six and 13 
months; Italy between age 13 to 15 months of age; Luxembourg at age 13 months; 
Netherlands at age 14 months; Spain at age four and 12 months, and the United 
Kingdom at age three and 13 months of age.  Two countries, Ireland and the United 
Kingdom, have meningococcal B vaccine in their routine immunisation plans, 
administered at age two, four, and 12 months of age.  
 
Figure 6: Meningococcal C and B primary immunisation schedules across European 
Union/European Economic Area. 
 
 
 
	
	
	 		 	
	
	
	 			
		 					
	
	
	 	
	
	
	 	
	
	 	
	 	
	
	
	
	
	
	
	Meningococcal C vaccine  
Meningococcal B 
vaccine  B 
B 
B 
		
	 22	
2.11. Measles 
Measles is the main cause of vaccine-preventable deaths in infants in the world 
[47]. Measles is a systemic infection [19], and measles virus is highly infectious. In 
the pre-vaccination period a high percentage of individuals were infected by age10 
[48]. This disease is transmitted by aerosolised respiratory droplets and by direct 
contact and it can be prevented with vaccination [48].  
Measles virus is an RNA virus composed of eight proteins; the structural proteins 
are essential in the pathogenesis of measles [2,48]. .Thus, lifelong immunity after 
disease is attributed to antibodies that neutralise one of those proteins [2,48]. The 
severity of the disease varies considerably depending on several host and 
environmental factors; for example, age below five years is a risk factor for severe or 
fatal measles [48]. Infants are usually protected against measles for six to nine months 
through transplacentally-acquired antibodies [48]. Therefore, vaccination before age 
six months frequently fails to induce seroconversion due to immune system 
immaturity and the presence of maternal antibodies [47]. High avidity antibodies are 
needed to develop protective immunity to measles, and response is usually less avid 
in children vaccinated at age six months or nine months, compared with the avidity 
obtained in children vaccinated at age 12 months [48]. WHO recommends that all 
children should be vaccinated with two doses of measles vaccine [48]. In countries 
where the risk for measles infection among infants is low, as in EU/EEA countries, 
the first dose should be given at age 12 months [48]. The second dose should be 
administered between the age of four to six years [2].  
In EU/EEA countries, the age for primary vaccination of measles varies 
considerably (Figure 7). For example, in Belgium, Croatia, Estonia, Finland, Ireland, 
Portugal, Romania, and Spain, it is administered at age 12 months. In the Czech 
Republic, Denmark, Hungary, and Norway, primary vaccination occurs at age 15 
months. The primary vaccination is provided at age 18 months in Iceland and Sweden 
(Figure 7).  
Measles vaccine is normally administered in combination with rubella and mumps 
as a live attenuated combined vaccine, and studies consistently show that the 
combined vaccines elicit the same high rates of seroconversion observed with each 
component individually [2]. Measles has been pointed for eradication in EU/EEA [49]. 
Measles notification was in 2015 below the elimination target  (one case per million 
population) in 14 of the 30 reporting countries [49]. Seven countries reported zero 
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cases and 16 had the notification rate above the elimination target, with Croatia 
reporting the highest rate (51.6 cases per million) followed by Austria (35.3 cases per 
million) and Germany (30.5 cases per million) [49].   
  
2.12. Mumps 
Mumps is a viral infection that primarily affects salivary glands [2]. Although it is 
normally a mild childhood disease, with a peak incidence between five to nine years 
of age, the virus can also affect adults, for whom complications are more frequent and 
severe than in children [50]. Humans are the only known natural host, and disease 
transmission is through direct contact or by airborne droplets from respiratory tract 
[50]. 
Mumps virus is a negative-strand RNA virus from the Paramyxoviridae family [2]. 
According to WHO routine mumps vaccination should be implemented in countries 
with a well-established and effective childhood vaccination schedule, and with the 
capacity to sustain elevated levels of vaccination coverage [50]. As, insufficient 
childhood vaccination coverage may lead to an epidemiological shift in the incidence 
of mumps to older age groups and possibly lead to a more severe disease burden than 
occurred before immunisation was introduced [50]. WHO considers measles and 
congenital rubella control a higher priority than mumps control [50]. When the 
implementation of mumps vaccine is determined, the use of the combined vaccine of 
mumps-measles-rubella is strongly recommended [50]. 
Mumps vaccine is normally administered in combination with rubella and mumps 
in EU/EEA countries. As for measles vaccine, the age for primary vaccination of 
mumps varies considerably (Figure 7). 
 
2.13. Rubella  
Rubella is an acute; normally mild and self-limited viral disease that usually 
affects susceptible children and young adults worldwide [51]. However, rubella virus 
has teratogenicity potential and, thus, is a public health concern [51]. When rubella 
infection occurs just before conception or during early pregnancy, foetal death or 
congenital defects, known as congenital rubella syndrome, may happen [51]. Rubella 
congenital syndrome includes a long list of abnormalities, as all organs of the foetus 
are affected [2].  
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Rubella virus is a togavirus [2]. Humans are the only known host, and it is 
transmitted by respiratory route [2]. Rubella vaccine is normally administered with 
mumps and measles in a combined live attenuated vaccine, and single or combined 
vaccines are highly efficacious [51]. Although a high response to a single dose of 
rubella vaccine and long-term persistence of protection do not support the need of a 
second dose, this second dose is, generally, administered based on the indications for 
a second dose of measles and mumps vaccines [51]. The main aim of rubella 
vaccination is the prevention of congenital rubella infection [51].  
Rubella vaccine is normally administered in combination with measles and 
mumps in EU/EEA countries. As for measles and mumps vaccine, the age for primary 
vaccination of rubella varies considerably (Figure 7).  
Rubella has been pointed for eradication in the EU/EEA [49].  In 2015, rubella 
notification rate was lower than the elimination target (one case per million 
population) in 25 of the 28 reporting countries in 2015 [49]. The higher rates were 
observed in Poland (53.4 cases per million), followed by Germany and Ireland (1.1 
and 1.3 cases per million, respectively) [49].  
 
Figure 7: Measles, mumps, and rubella primary immunisation schedules across European 
Union/European Economic Area. 
 
 
	
	
	 		 	
	
	
	 			
		 					
	
	
	 	
	
	
	 	
	
	 	
	 	
	
	
	
	
	
	
	11 months 	12 months 	13 months 	15 months 	11-14 months 	12-15 months 	18 months 	15-16 months 	14 months 	13-14 months 	14-17 months 	12-18 months 	12-13 months 
		
	 25	
3. Conclusion 
The EU/EEA is composed of a diverse group of countries and a large variation of 
early childhood immunization schedules and included vaccines were observed across 
countries in this review. The considerable variation observed in the early childhood 
immunization series among different EU/EEA countries, concerning both vaccines 
included and immunisation schedules, have raised some questions and concerns. One 
such concern is the mobility across the EU/EEA of young children travelling or 
moving, since they can easily miss a dose or booster. An ideal solution would be an 
uniform EU/EEA immunisation schedule (Table 2).  
WHO recommends that rotavirus vaccine should be included in all national 
immunisation programmes, and considers it a priority. Therefore, we would also 
suggest considering the inclusion of this vaccine in the EU/EEA immunisation 
schedule. The vaccine would be given at age two and four months to coincide with 
DTPa schedule and to reduce the number of visits to medical facilities.  
Concerning DTPa vaccine, some interference is likely between maternal 
antibodies and diphtheria vaccine [22]. Thus, it would be better to only administer 
diphtheria vaccine at age two months or after. However, since it is a combined 
vaccine, pertussis vaccine should be given as early as possible, at the age of six weeks 
according to WHO, since pertussis is of particularly risk for young infants. For 
tetanus vaccine, age at first dose does not seem critical, which is owed to its great 
immunogenicity and because maternal antibodies presumably do not interfere with 
neonatal responses [22]. We suggest that the primary schedule for DTPa should be 
provided at two, three, and four months, as protection for pertussis is reached earlier 
[22]. An alternative is maternal immunisation between 28 and 38 weeks’ gestation, 
which is already being executed in countries such as the United Kingdom and 
Portugal.   
Since the WHO region was officially declared polio-free, no special schedule is 
needed for polio vaccine. Therefore, and due to the inherent convenience of reducing 
the number of visits to medical facilities, polio vaccine would have the same schedule 
of DTPa vaccine: two, three, and four months. Hib vaccine schedule should also be 
the same. 
WHO recommends the administration of hepatitis B vaccine as soon as possible 
after birth, preferable in the first 24 hours, even in low-endemicity countries [36]; this 
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dose should be followed by two or three doses with a minimum interval of four weeks 
to complete the primary series. Based on this hepatitis B vaccine, the primary 
schedule in the EU/EEA would be: birth, two, and four months.  
The first dose of pneumococcal vaccine should be, according to WHO, 
administered as early as six weeks of age, with the second dose at an interval of eight 
weeks [37]. Based on this, the primary series of this vaccine in the EU/EEA 
immunisation schedule would be at two and four months of age.  
Meningococcal C vaccine would be included in the immunisation plan and 
administered at age 12 months, as recommended by WHO [41]. Since the majority of 
cases are now caused by serogroup B in the EU/EEA, particularly in countries that 
have introduced serogroup C meningococcal conjugate vaccine [41], the inclusion of 
meningococcal B vaccine should be considered as part of the EU/EEA immunisation 
plan with the primary schedule of two, four, and six months. Measles, mumps, and 
rubella vaccine primary immunisations would be administered at age 12 months, as 
high avidity antibodies for measles are achieved at age 12 months [47]. 
Given the growing number of people moving around the EU/EEA, including 
young couples with young children, a common schedule might have a positive impact 
on vaccinations [21]. Therefore, even though early childhood immunization schedules 
in the EU/EEA are safe and effective, the significant difference observed between 
countries might cause constraints in vaccination. Therefore, we present a 
recommendation, based on the available knowledge, for the early childhood 
immunization schedule the EU/EEA. To the best of our knowledge, this is the first 
review presenting a suggestion for the early childhood immunization schedule in the 
EU/EEA. 
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Table 2: Primary immunization schedule proposal for countries that for European Union/European Economic Area. 
 
 
* as soon as possible after birth in countries with high incidence. Hib= Haemophilus influenzae type B.  Hexavalent vaccine (combined vaccine against diphtheria, tetanus, 
pertussis, poliomyelitis, Hib and hepatitis B) can be used to reduce the number of injections at 2 and 4 months and heptavalent (combined vaccine against diphtheria, tetanus, 
pertussis, poliomyelitis and Hib) at 3 months.  
Tuberculosis  Rotavirus  Diphtheria -
Tetanus -
Pertussis  
Poliomyelitis Hib Hepatitis B Pneumococcal 
disesase  
Meningococcal 
disease C 
Meningococcal 
disease B 
Measles -
Mumps -
Rubella 
0* 2, 4 months  2,3 and 4 
months  + 18 
months  
2,3 and 4 
months + 18 
months  
2,3 and 4 
months + 18 
months  
0, 2 and 4 
months  
2 and 4 months 
+ 12 months  
12 months  2, 4 months + 
18 months 
12 months  
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Vaccination effectors   
Introduction 
Active immunity refers to the process of exposing the body to an antigen to 
generate an adaptive immune response that is long-lasting [1]. Active immunity can 
be acquired by vaccination or through exposure to the disease [1]. Vaccines interact 
with the immune system and usually create a response similar to those produced by 
the infection without subjecting an individual to the disease and its complications [2].   
Antigens, which are present in vaccines, can be live (as viruses or bacteria), or 
inactivated or genetically-engineered vaccines. The immune system will develop a 
specific response to the antigens, and it normally involves the production of 
antibodies (immunoglobulins; humoral immunity) and of specific cells, including T 
and B cells (cell-mediated immunity), whose aim is to facilitate the elimination of a 
pathogen [2].  
 
Vaccine types  
Vaccines can be categorised into wide groups: live attenuated vaccines, and 
inactivated (subunit, toxoid carbohydrate, and conjugate) vaccines [3]. Subunit 
vaccines can be subdivided into those for which the antigen is produced using 
recombinant DNA technology, and those based on normal bacteriological growth 
processes [1].  
The first group of vaccines contains attenuated forms of the pathogen that mimic 
the immune response elicited by the pathogen itself [3]. Live attenuated vaccines 
(viruses or bacteria) cause a strong cellular and antibody response; their immunity 
lasts for several decades, even with only a single dose (except for those administered 
orally) [3]. Nevertheless, a percentage of receivers do not respond to the first dose of 
an injected live vaccine, thus, a second dose is recommended to provide a high level 
of population immunity [2]. The development of active immunity to a certain live 
vaccine can be affected by circulating antibodies to the vaccine virus, as the ones 
transferred through placenta [2]. This may lead to a poor or no response to the vaccine 
[2]. This group of vaccines can provide a lifelong memory [3]. 
The vaccines of the second group can be composed of either whole viruses or 
bacteria or fractions of them [2]. Fractional vaccines are protein-based or 
polysaccharide (PS)-based [2]. Protein-based vaccines include toxoids (inactivated 
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bacterial toxin) and subunit or subviron products [2]. PS-based vaccines are 
composed of pure cell wall PS from bacteria [2]. Conjugate polysaccharide vaccines 
contain PS that are chemically linked to a protein, which causes the PS to be more 
potent [2]. Normally, these vaccines contain substances named adjuvants that increase 
the magnitude and quality of the immune response [3]. The circulating antibodies do 
not influence the response to an inactivated vaccine and, therefore, they can be 
administered when the antibody is present in the blood [2]. This group of vaccines do 
not provide a lifelong memory [3]. Thus, several boosters are needed to maintain 
protective immunity [3]. A protective immune response is not developed in the first 
dose, and usually only occurs after the second or third dose [2]. Furthermore, the 
immune response to these groups of vaccines is mostly humoral, and little or no 
cellular immunity is observed [2]. The response to a pure PS vaccine is classically a 
T-independent response [2]. Therefore, these vaccines can stimulate B-cells without 
the assistance of T-helper (Th) cells [2]. These types of vaccines and all T-cell-
independent antigens are not consistently immunogenic in children below two years 
of age, as the immune system is still immature [2]. In addition, PS vaccines 
predominantly produce IgM and little IgG antibodies, resulting in less effective 
vaccines [2]. To solve this problem, PS began to bind to protein in a process called 
conjugation. Through this process, the immune response changes from T-independent 
to T-dependent [2].  
 
Vaccines mechanisms  
A prerequisite of a vaccine is to elicit adequate alert signals through antigens or 
adjuvants that trigger inflammatory response mediated by cells of the innate immune 
system [4]. Various cells, such as dendritic cells (DCs), monocytes, and neutrophils, 
express pattern recognition receptors (PRRs) as toll-like receptors (TLRs) that are 
capable of reacting to a signal [3,4]. Through these receptors, after encountering the 
pathogen, the cells can become activated and produce pro-inflammatory cytokines 
and chemokines that will attract monocytes, granulocytes, and natural killer cells [4]. 
These organisms generate an essential inflammatory microenvironment in which 
monocytes differentiate into macrophages and immature DCs become activated [4]. 
After activation, DCs will migrate to lymph nodes and present the antigen to B- and 
T- cells that are activated [4]. Live viral vaccines trigger the innate immune system 
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more efficiently through pathogen-associated signals that are recognised by PRRs [4].  
After the administration of a live vaccine, the pathogen rapidly disseminates and DCs 
are activated at multiple sites [4]. Therefore, the early diffusion of live vaccines 
causes the site and route of administration to be less important than for non-live 
vaccines [4]. Non-live vaccines mainly activate innate immune responses at their site 
of injection [4]. Thus, their site and route of administration are very important. For 
example, the high number of DCs in dermis permits a reduction of the antigen 
concentration in intradermal vaccines [4].   
B-cells are mainly activated in the lymph nodes [4]. Then, B-cells engage with T-
cells and initiate their proliferation [4]. Consequently, antigen-specific B-cells interact 
with activated DCs and T-cells [4]. T-cells contribute to B-cell differentiation and 
production of immunoglobulin-secreting plasma cells that produce antibodies [4]. 
During B-cell differentiation, immunoglobulin IgM undergoes recombination and 
switches to IgG, IgA, or IgE. This allows the production of highly specific antibodies 
[4]. T-cells CD4+, Th1, and Th2 have an essential role as helpers, as their CD40L 
molecules engage with CD40 of B-cells, allowing the class switch of 
immunoglobulins [4]. Antigen-specific B-cells, which receive help from antigen-
specific activated T-cells, endure differentiation into plasma cells or memory B-cells 
[4].  
The conjugation of a pathogen PS with a protein carrier elicits antigen-specific 
CD4+ Th cells, a T-dependent antibody response [4]. This response produces highly-
differentiated B-cell differentiation that allows the production of antibodies, as 
previously mentioned [4]. The T-dependent response can be provoked by toxoid, 
protein, inactivated, or live attenuated viral vaccines, and is capable of producing 
higher affinity antibodies and immune memory [4]. In addition, live attenuated 
vaccines normally generate CD8+ cytotoxic T-cells [4]. Currently, the majority of the 
existent vaccines mediate their protective efficacies through the induction of highly 
specific IgG antibodies [4]. Antigen-specific antibodies have been confirmed to 
confer vaccine-induced protection against many diseases [4]. The removal of a 
pathogen from mucosal surface implies the presence of vaccine-induced IgG 
antibodies, and its concentration needs to be in great abundance and possess much 
affinity to facilitate the antibody titre in saliva and mucosal secretions [4]. Usually, 
this response is elicited by a glycoconjugate vaccine. Normally, vaccination does not 
prevent local infection of the mucosa if it is only after the infection that vaccine-
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induced IgG serum antibodies neutralise the pathogen and limit its proliferation and 
spread [4]. 	
References  	1.	 Baxter	 D.	 Active	 and	 passive	 immunity,	 vaccine	 types,	 excipients	 and	licensing.	Occup	Med	(Lond),	57(8),	552-556	(2007).	2.	 Epidemiology	 and	 Prevention	 of	 Vaccine-Preventable	 Diseases	 (eds.	Hamborsky,	 J,	 Kroger,	 A,	 Wolfe,	 C)	 (Centers	 for	 Diseade	 Control	 and	Prevention.	,	2015	).	3.	 Pulendran	 B,	 Ahmed	 R.	 Immunological	 mechanisms	 of	 vaccination.	Nat	
Immunol,	12(6),	509-517	(2011).	4.	 Plotkin	SA,	Orenstein	WA,	A.Offit	P.	Vaccines	(Elsevier	Saunders	2013).		
